Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00707174 · ClinicalTrials.gov registry record · NA
Combination Therapy With Imiquimod Cream 5% and Tazarotene Cream 0.1% for the Treatment of Lentigo Maligna
A NA study, sponsored by University of Utah.
- Completed
- Registry status
- NA
- Development phase
- 90
- Enrollment target
NCT00707174 is a NA study that has completed, run by University of Utah. The registered enrollment target is 90 participants.
The verdict
NCT00707174, a NA study, has completed, sponsored by University of Utah.
- COMPLETED
- Registry status
- NA
- Development phase
- 90 participants
- Enrollment target
Study Summary
This study is designed as a randomized, prospective study to test the efficacy of imiquimod plus tazarotene in the treatment of LM. Eligible and consented patients will be randomized to one of two treatment groups: 1) topical imiquimod group, or 2) topical imiquimod combined with topical tazarotene group. All patients will undergo a staged surgical excision with rush permanent sections to confirm negative histologic margins. This will be followed by a surgical repair of the defect and long-term follow-up of five years to rule out recurrences. Both groups will have a polygonal excision using 2mm margins per stage.
Interventions
- DRUG Imiquimod Cream
- DRUG Tazarotene Cream 0.1%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2005-03 |
| Est. Completion | 2013-03 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00707174
The ClinicalTrials.gov registry entry for NCT00707174 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Utah, which has 818 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Imiquimod Cream is the first listed.
NCT00707174 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00707174 about?
NCT00707174 is a clinical study titled "Combination Therapy With Imiquimod Cream 5% and Tazarotene Cream 0.1% for the Treatment of Lentigo Maligna". This study is designed as a randomized, prospective study to test the efficacy of imiquimod plus tazarotene in the treatment of LM. Eligible and consented patients will be randomized to one of two treatment groups: 1) topical imiquimod group, or 2) topical imiquimod combined with topical tazarotene ...
What is the current status of trial NCT00707174?
This trial is currently completed. It is a NA study. The enrollment target is 90 participants. The study started on 2005-03. Estimated completion is 2013-03.
What interventions are being tested in trial NCT00707174?
The interventions under investigation include: Imiquimod Cream (DRUG), Tazarotene Cream 0.1% (DRUG).
Who is sponsoring clinical trial NCT00707174?
This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.